Literature DB >> 1634805

Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

U Bruderer1, S J Cryz, U B Schaad, M Deusinger, J U Que, A B Lang.   

Abstract

Naturally acquired anti-Pseudomonas aeruginosa antibody fails to afford protection against repeated P. aeruginosa bronchopulmonary exacerbations in cystic fibrosis (CF) patients. In an effort to explain this phenomenon, the titer and affinity constants of serum anti-lipopolysaccharide (LPS) IgG were determined in five study groups: healthy adults before and after immunization with a polyvalent LPS-based vaccine, healthy noncolonized CF patients before and after immunization, nonimmunized CF patients with significantly elevated anti-LPS antibody titers without documented colonization, recently colonized CF patients before and after immunization, and nonimmunized CF patients chronically colonized with P. aeruginosa. Immunization elicited a significant rise in total anti-LPS immunoglobulin levels and affinity constants in both healthy adults and CF patients. Although chronically colonized patients had elevated levels of total anti-LPS antibody, these antibodies possessed affinities at least 100-fold less than those of vaccine-induced antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634805     DOI: 10.1093/infdis/166.2.344

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

Authors:  O Ciofu; T D Petersen; P Jensen; N Høiby
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

3.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

4.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  Amount and Avidity of IgG Antibodies to Pseudomonas Aeruginosa Exotoxin A Antigen in Cystic Fibrosis Patients.

Authors:  Janja Polanec; Jan Patzer; Jacek Grzybowski; Milan Strukelj; Zlatko P Pavelic
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Immune selection for antigenic drift of major outer membrane protein P2 of Haemophilus influenzae during persistence in subcutaneous tissue cages in rabbits.

Authors:  L Vogel; B Duim; F Geluk; P Eijk; H Jansen; J Dankert; L vanAlphen
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.

Authors:  Yanyan Li; Zhenling Wang; Xiaoxiao Liu; Jianying Tang; Bin Peng; Yuquan Wei
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

9.  Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Jesse Cimino; Ziqiang Guan; Wei Sun
Journal:  Infect Immun       Date:  2021-07-26       Impact factor: 3.609

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.